Assembly Biosciences, Inc. Retained Earnings
Assembly Biosciences, Inc. (ASMB) had Retained Earnings of -$844.98 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$844.98M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$841.13M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$832.05M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$854.14M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$844.98M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | -$841.13M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | -$832.05M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | -$854.14M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | -$844.94M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | -$834.74M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | -$825.92M 10-K · filed 2026-03-19 | |
| 2024-09-30 | -$815.59M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | -$805.98M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | -$794.83M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | -$785.75M 10-K · filed 2025-03-20 | |
| 2023-09-30 | -$774.79M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | -$760.37M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | -$743.47M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | -$724.52M 10-K · filed 2024-03-28 | |
| 2022-09-30 | -$702.13M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | -$678.98M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | -$654.52M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | -$631.43M 10-K · filed 2023-03-22 | |
| 2021-09-30 | -$571.17M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | -$552.37M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | -$528.77M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | -$501.57M 10-K · filed 2022-03-11 | |
| 2020-09-30 | -$462.15M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | -$458.81M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | -$466.08M 10-Q · filed 2020-05-08 | |
| 2019-12-31 | -$439.42M 10-K · filed 2021-02-25 | |
| 2019-09-30 | -$412.34M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | -$387.34M 10-Q · filed 2019-08-05 | |
| 2019-03-31 | -$368.84M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | -$341.79M 10-K · filed 2020-03-04 | |
| 2018-09-30 | -$315.63M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | -$294.09M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | -$267.28M 10-Q · filed 2018-05-07 | |
| 2017-12-31 | -$251.04M 10-K · filed 2019-02-28 | -$251.04M 10-K · filed 2018-03-08 |
| 2017-09-30 | -$248.03M 10-Q · filed 2017-11-01 | |
| 2017-06-30 | -$235.76M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | -$222.16M 10-Q · filed 2017-05-08 | |
| 2016-12-31 | -$208.23M 10-K · filed 2018-03-08 | |
| 2016-09-30 | -$196.68M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | -$185.11M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | -$174.95M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | -$163.97M 10-K · filed 2017-03-02 | |
| 2015-09-30 | -$156.22M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | -$149.60M 10-Q · filed 2015-08-13 | |
| 2015-03-31 | -$142.66M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | -$135.51M 10-K · filed 2016-03-11 | |
| 2014-09-30 | -$129.28M 10-Q · filed 2014-11-17 | |
| 2013-12-31 | -$111.72M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |